An interventional study of plasma exchange and conservative treatment in Acute Pancreatitis, sponsored by University Medical Centre Ljubljana. Completed at 1 site in Slovenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-30.
Sponsored by University Medical Centre Ljubljana · Not applicable, Interventional, and Treatment
To compare effectiveness in reducing triglycerides between daily plasma exchange and glucose+insulin infusion in patients with non-severe acute hypertriglyceridemic pancreatitis with mildly elevated triglycerides
752 studies on the registry are indexed under Pancreatitis; 181 are open to participants now.
This study's enrollment of 22 is below the median of 80 across 448 interventional studies indexed under Pancreatitis.
Browse Pancreatitis studies →University Medical Centre Ljubljana is the lead sponsor of 284 studies on the registry; 71 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
plasma exchange, with 1.5 estimated plasma volume exchanged with albumin solution, using citrate anticoagulation, performed daily until triglycerides \<=10 mmol/l
Procedure: plasma exchange
infusion of 5% glucose and insulin, to maintain blood glucose at 5-8 mmol/l
Drug: conservative treatment
see arm description
see arm description
Also known as: glucose and insulin
decrease in triglycerides
as % of starting value
Time frame: within first 24 h after admission
time until triglycerides drop to <10 mmol/l
expressed in days
Time frame: by the end of hospital stay, up to 100 days
highest C-reactive protein (CRP)
Time frame: by the end of hospital stay, up to 100 days
% of patients with severe pancreatitis
Time frame: by the end of hospital stay, up to 100 days
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Centre Ljubljana